Sign in or Register   Sign in or Register
  |  

Mouse Anti-IL5 Recombinant Antibody (CBYY-I0800) (CBMAB-I1781-YY)

This product is Mouse antibody that recognizes IL5. The antibody CBYY-I0800 can be used for immunoassay techniques such as: ELISA, FC, IHC, WB
See all IL5 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-I0800
Antibody Isotype
IgG1
Application
ELISA, FC, IHC, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Lyophilized
Buffer
5% trehalose
Concentration
0.5 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Interleukin 5
Introduction
This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31.
Entrez Gene ID
UniProt ID
Alternative Names
Interleukin 5
Function
Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.
Biological Process
Cytokine-mediated signaling pathwayIEA:Ensembl
Immune responseIEA:InterPro
Inflammatory responseManual Assertion Based On ExperimentTAS:ProtInc
Positive regulation of B cell proliferationIEA:Ensembl
Positive regulation of DNA-binding transcription factor activityIEA:Ensembl
Positive regulation of eosinophil differentiationIEA:Ensembl
Positive regulation of immunoglobulin productionIEA:Ensembl
Positive regulation of peptidyl-tyrosine phosphorylationISS:UniProtKB
Positive regulation of podosome assemblyManual Assertion Based On ExperimentIDA:BHF-UCL
Positive regulation of receptor signaling pathway via JAK-STATIEA:Ensembl
Positive regulation of transcription, DNA-templatedIEA:Ensembl
Cellular Location
Secreted

Maglio, A., Vitale, C., Pelaia, C., D’Amato, M., Ciampo, L., Sferra, E., ... & Vatrella, A. (2023). Severe asthma remissions induced by biologics targeting IL5/IL5r: results from a multicenter real-life study. International Journal of Molecular Sciences, 24(3), 2455.

Van Hulst, G., Jorssen, J., Jacobs, N., Henket, M., Louis, R., Schleich, F., ... & Desmet, C. J. (2022). Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma. European Respiratory Journal, 59(3).

Mümmler, C., Suhling, H., Walter, J., Kneidinger, N., Buhl, R., Kayser, M. Z., ... & Milger, K. (2022). Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice, 10(12), 3174-3183.

Pala, D., & Pistis, M. (2021). Anti-IL5 drugs in COVID-19 patients: role of eosinophils in SARS-CoV-2-induced immunopathology. Frontiers in pharmacology, 12, 622554.

Bjerrum, A. S., Skjold, T., & Schmid, J. M. (2021). Oral corticosteroid sparing effects of anti-IL5/anti-IL5 receptor treatment after 2 years of treatment. Respiratory Medicine, 176, 106260.

Martínez-Moragón, E., García-Moguel, I., Nuevo, J., & Resler, G. (2021). Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulmonary Medicine, 21(1), 1-12.

Menzella, F., Ruggiero, P., Ghidoni, G., Fontana, M., Bagnasco, D., Livrieri, F., ... & Facciolongo, N. (2020). Anti-IL5 therapies for severe eosinophilic asthma: literature review and practical insights. Journal of Asthma and Allergy, 301-313.

Rademacher, J., Konwert, S., Fuge, J., Dettmer, S., Welte, T., & Ringshausen, F. C. (2020). Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. European Respiratory Journal, 55(1).

Marc-Malovrh, M., Camlek, L., Škrgat, S., Kern, I., Fležar, M., Dežman, M., & Korošec, P. (2020). Elevated eosinophils, IL5 and IL8 in induced sputum in asthma patients with accelerated FEV1 decline. Respiratory Medicine, 162, 105875.

Ramonell, R. P., & Iftikhar, I. H. (2020). Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis. Lung, 198, 95-103.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-IL5 Recombinant Antibody (CBYY-I0800)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare